Literature DB >> 26020282

Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study.

M Noureddin1, Y Rotman2, F Zhang2, H Park3, B Rehermann3, E Thomas2, T J Liang2.   

Abstract

IFNL4 is linked to hepatitis C virus treatment response and type III interferons (IFNs). We studied the functional associations among hepatic expressions of IFNs and IFN-stimulated genes (ISGs), and treatment response to peginterferon and ribavirin. Type I IFNs (IFNA1, IFNB1), type II (IFNG), type III (IFNL1, IFNL2/3), IFNL4 and ISG hepatic expressions were measured by qPCR from in 65 chronic hepatitis C (CHC) patients whose IFNL4-associated rs368234815 and IFNL3-associated rs12989760 genotype were determined. There was a robust correlation of hepatic expression within type I and type III IFNs and between type III IFNs and IFNL4 but no correlation between other IFN types. Expression of ISGs correlated with type III IFNs and IFNL4 but not with type I IFNs. Levels of ISGs and IFNL2/3 mRNAs were lower in IFNL3 rs12979860 CC patients compared with non-CC patients, and in treatment responders, compared with nonresponders. IFNL4-ΔG genotype was associated with high ISG levels and nonresponse. Hepatic levels of ISGs in CHC are associated with IFNL2/3 and IFNL4 expression, suggesting that IFNLs, not other types of IFNs, drive ISG expression. Hepatic IFNL2/3 expression is functionally linked to IFNL4 and IFNL3 polymorphisms, potentially explaining the tight association among ISG expression and treatment response.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26020282      PMCID: PMC6015498          DOI: 10.1038/gene.2015.11

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  38 in total

1.  Direct multiplexed measurement of gene expression with color-coded probe pairs.

Authors:  Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

2.  Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43.

Authors:  Magdalena Sarasin-Filipowicz; Xueya Wang; Ming Yan; Francois H T Duong; Valeria Poli; Douglas J Hilton; Dong-Er Zhang; Markus H Heim
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

3.  Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

Authors:  Masao Honda; Akito Sakai; Tatsuya Yamashita; Yasunari Nakamoto; Eishiro Mizukoshi; Yoshio Sakai; Taro Yamashita; Mikiko Nakamura; Takayoshi Shirasaki; Katsuhisa Horimoto; Yasuhito Tanaka; Katsushi Tokunaga; Masashi Mizokami; Shuichi Kaneko
Journal:  Gastroenterology       Date:  2010-04-29       Impact factor: 22.682

4.  HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.

Authors:  Emmanuel Thomas; Veronica D Gonzalez; Qisheng Li; Ankit A Modi; Weiping Chen; Mazen Noureddin; Yaron Rotman; T Jake Liang
Journal:  Gastroenterology       Date:  2012-01-13       Impact factor: 22.682

Review 5.  IL28B and the control of hepatitis C virus infection.

Authors:  Ashwin Balagopal; David L Thomas; Chloe L Thio
Journal:  Gastroenterology       Date:  2010-10-13       Impact factor: 22.682

6.  Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.

Authors:  Yasuhiro Asahina; Kaoru Tsuchiya; Masaru Muraoka; Keisuke Tanaka; Yuichiro Suzuki; Nobuharu Tamaki; Yoshihide Hoshioka; Yutaka Yasui; Tomoji Katoh; Takanori Hosokawa; Ken Ueda; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Masayuki Kurosaki; Nobuyuki Enomoto; Sayuri Nitta; Naoya Sakamoto; Namiki Izumi
Journal:  Hepatology       Date:  2011-11-29       Impact factor: 17.425

7.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

8.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

9.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

10.  Interferon-λ4 (IFNL4) transcript expression in human liver tissue samples.

Authors:  Ahmad Amanzada; Waltraut Kopp; Ulrich Spengler; Giuliano Ramadori; Sabine Mihm
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

View more
  16 in total

1.  Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.

Authors:  Xiaoming Cheng; Takuro Uchida; Yuchen Xia; Regina Umarova; Chun-Jen Liu; Pei-Jer Chen; Anuj Gaggar; Vithika Suri; Marcus M Mücke; Johannes Vermehren; Stefan Zeuzem; Yuji Teraoka; Mitsutaka Osawa; Hiroshi Aikata; Keiji Tsuji; Nami Mori; Shuhei Hige; Yoshiyasu Karino; Michio Imamura; Kazuaki Chayama; T Jake Liang
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

2.  Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.

Authors:  Hawwa Alao; Maggie Cam; Chithra Keembiyehetty; Fang Zhang; Elisavet Serti; Daniel Suarez; Heiyoung Park; Nicolaas H Fourie; Elizabeth C Wright; Wendy A Henderson; Qisheng Li; T Jake Liang; Barbara Rehermann; Marc G Ghany
Journal:  Hepatology       Date:  2018-07-16       Impact factor: 17.425

3.  Tetrabromobisphenol A activates the hepatic interferon pathway in rats.

Authors:  J K Dunnick; D L Morgan; S A Elmore; K Gerrish; A Pandiri; T V Ton; K R Shockley; B A Merrick
Journal:  Toxicol Lett       Date:  2016-11-30       Impact factor: 4.372

4.  Possible relationship between IL28B rs12979860 and TLR2 -196 to -174 del/ins polymorphisms and the liver fibrosis stage in hepatitis C patients.

Authors:  Zehra Öksüz; Enver Üçbilek; Mehmet Sami Serin; Serkan Yaraş; Gülhan Örekici Temel; Orhan Sezgin
Journal:  Arch Virol       Date:  2021-11-24       Impact factor: 2.574

5.  Interferon lambda4 polymorphism is not associated with human papillomavirus infection outcome.

Authors:  Fabiana Cannella; Carolina Scagnolari; Maura Statzu; Ilaria Sciandra; Nadia Recine; Gabriella d'Ettorre; Guido Antonelli; Alessandra Pierangeli
Journal:  Virus Genes       Date:  2017-12-14       Impact factor: 2.332

6.  Hepatitis E virus persists in the presence of a type III interferon response.

Authors:  Xin Yin; Xinlei Li; Charuta Ambardekar; Zhimin Hu; Sébastien Lhomme; Zongdi Feng
Journal:  PLoS Pathog       Date:  2017-05-30       Impact factor: 6.823

7.  Hepatic Interferon-λ3 (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C.

Authors:  Ahmad Amanzada; Lars Reinhardt; Dorothea Fey; Elisabeth M Zeisberg; Sabine Mihm
Journal:  PLoS One       Date:  2015-11-25       Impact factor: 3.240

8.  The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors.

Authors:  Linh Thuy Nguyen; Emma Gray; Aisling O'Leary; Michael Carr; Cillian F De Gascun
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

Review 9.  Interferon Response in Hepatitis C Virus (HCV) Infection: Lessons from Cell Culture Systems of HCV Infection.

Authors:  Pil Soo Sung; Eui-Cheol Shin; Seung Kew Yoon
Journal:  Int J Mol Sci       Date:  2015-10-07       Impact factor: 5.923

10.  HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2.

Authors:  Valli De Re; Mariangela De Zorzi; Laura Caggiari; Gianfranco Lauletta; Maria Lina Tornesello; Elisa Fognani; Marta Miorin; Vito Racanelli; Luca Quartuccio; Laura Gragnani; Sabino Russi; Fabio Pavone; Michela Ghersetti; Elena Garlatti Costa; Pietro Casarin; Riccardo Bomben; Cesare Mazzaro; Giancarlo Basaglia; Massimiliano Berretta; Emanuela Vaccher; Francesco Izzo; Franco Maria Buonaguro; Salvatore De Vita; Anna Linda Zignego; Paolo De Paoli; Riccardo Dolcetti
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.